937013-66-6

Basic information

• Product Name: 2-(3-BROMO-PHENYL)-1H-IMIDAZOLE
• Synonyms: 2-(3-BROMO-PHENYL)-1H-IMIDAZOLE;2-(3-BroMophenyl)iMidazole;1H-IMidazole, 2-(3-broMophenyl)-
• CAS NO: 937013-66-6
• Molecular Formula: C₉H₇BrN₂
• Molecular Weight: 223.06928
• Mol File: 937013-66-6.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 398.6±25.0 °C(Predicted)
• Appearance: /
• Density: 1.565±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 12.60±0.12(Predicted)
• CAS DataBase Reference: 2-(3-BROMO-PHENYL)-1H-IMIDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-BROMO-PHENYL)-1H-IMIDAZOLE(937013-66-6)
• EPA Substance Registry System: 2-(3-BROMO-PHENYL)-1H-IMIDAZOLE(937013-66-6)

Safety Data

• Hazardous Substances Data: 937013-66-6(Hazardous Substances Data)

Usage

General Description

2-(3-Bromo-phenyl)-1H-imidazole is a chemical compound that consists of an imidazole ring, which is a five-membered ring with two non-adjacent nitrogen atoms, attached to a bromo-phenyl group, which is a six-membered aromatic ring containing one bromine atom. The imidazole ring gives this compound its distinctive properties, which makes it important in many biochemical processes. It's often used in the synthesis of pharmaceuticals and other biologically active compounds due to its versatility and chemical stability. The properties, reactivity, and uses of this compound can be largely attributed to the presence and arrangement of its functional groups. It is an important intermediate in material chemistry and the synthesis of drugs.

Upstream product

• 3132-99-8 m-bromobenzoic aldehyde 
• 131543-46-9 Glyoxal 
• 56108-13-5 methyl 3-bromobenzenecarboximidoate hydrochloride 
• 6952-59-6 3-cyanobromobenzene 
• 16681-56-4 2-bromo-1H-imidazole 
• 89598-96-9 (3-bromophenyl)boronic acid 
• 1007578-88-2 N-[2,2-bis(ethyloxy)ethyl]-3-bromobenzene carboximidamide 

Relevant articles and documents

An Angle on MK2 Inhibition—Optimization and Evaluation of Prevention of Activation Inhibitors

The mitogen-activated protein kinase p38α pathway has been an attractive target for the treatment of inflammatory conditions such as rheumatoid arthritis. While a number of p38α inhibitors have been taken to the clinic, they have been limited by their efficacy and toxicological profile. A lead identification program was initiated to selectively target prevention of activation (PoA) of mitogen-activated protein kinase-activated protein kinase 2 (MK2) rather than mitogen- and stress-activated protein kinase 1 (MSK1), both immediate downstream substrates of p38α, to improve the efficacy/safety profile over direct p38α inhibition. Starting with a series of pyrazole amide PoA MK2 inhibitor leads, and guided by structural chemistry and rational design, a highly selective imidazole 9 (2-(3′-(2-amino-2-oxoethyl)-[1,1′-biphenyl]-3-yl)-N-(5-(N,N-dimethylsulfamoyl)-2-methylphenyl)-1-propyl-1H-imidazole-5-carboxamide) and the orally bioavailable imidazole 18 (3-methyl-N-(2-methyl-5-sulfamoylphenyl)-2-(o-tolyl)imidazole-4-carboxamide) were discovered. The PoA concept was further evaluated by protein immunoblotting, which showed that the optimized PoA MK2 compounds, despite their biochemical selectivity against MSK1 phosphorylation, behaved similarly to p38 inhibitors in cellular signaling. This study highlights the importance of selective tool compounds in untangling complex signaling pathways, and although 9 and 18 were not differentiated from p38α inhibitors in a cellular context, they are still useful tools for further research directed to understand the role of MK2 in the p38α signaling pathway.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS

Novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, pharmaceutical compositions containing them, to processes for their preparation.

Discovery of biaryl inhibitors of H+/K+ ATPase

We report the identification of a novel biaryl template for H+/K+ ATPase inhibition. Evaluation of critical SAR features within the biaryl imidazole framework and the use of pharmacophore modelling against known imidazopyridine and azaindole templates suggested that the geometry of the molecule is key to achieving activity. Herein we present our work optimising the potency of the molecule through modifications and substitutions to each of the ring systems. In particular sub-micromolar potency is achieved with (4b) presumably through a proposed intramolecular hydrogen bond that ensures the required imidazole basic centre is appropriately located.